ClinicalTrials.gg
RecruitingNCT05329714PVRI GoDeepUpdated Apr 4, 2025

PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension

An observational study in Pulmonary Hypertension and Global Health, sponsored by University of Giessen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University of Giessen · Observational

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
40,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.

Planned enrollment
Largest of 11
40,000 · median 500
Started
2020
with 1 other
Observational
11 of 13
5 open now
Registered
11th of 13
by date

Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2020, is one of 11 observational ones, and was the 11th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hypertension, Pulmonary by University of Giessen, or all of them as a file.
02

Study summary

PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.

Read the detailed description

PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center.

Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.

The data provided by PVRI-GoDeep will support academia to perform scientific projects in the field of PH. Pharmaceutical / commercial companies will be charged fee for access to PVRI-GoDeep data and / or analysis, thereby creating revenues exclusively devoted to support the PVRI mission and the registries entering their data into PVRI-GoDeep. All requests from academia or commercial companies are to be decided by the PVRI-GoDeep consortium, serving as Use and Access Committee.

03

Conditions studied

  • Pulmonary Hypertension
  • Global Health

Keywords

  • Pulmonary Hypertension
  • Data Integration
  • Standardization
  • Global Health
  • Quality Indicators
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Global cohort of patients with pulmonary hypertension (PH)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical Diagnosis of Pulmonary Hypertension

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
40,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Pulmonary Hypertension

    Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization.

  • Control Group

    Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension

06

What researchers measure

Primary outcomes

  1. Global analysis of PH patients

    Global comparison and analysis of the course of disease of PH patients

    Time frame: From entry into the registry up to 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jan 2050, 360 months after the start.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 360 months is above that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2022
First posted
Apr 15, 2022
StartActual
Jan 30, 2020
Primary completionEst.
Jan 30, 2050
CompletionEst.
Jan 30, 2055
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05329714
Lead sponsor
University of Giessen
Collaborators
Imperial College London, Johns Hopkins University, Stanford University, University of Sheffield, University of Pittsburgh, University of Pavia, Hospital de Niños de la Santísima Trinidad, Academy of Medical Sciences of Ukraine, The Methodist Hospital Research Institute, Vanderbilt University Medical Center, Mayo Clinic, National and Kapodistrian University of Athens, Aristotle University Of Thessaloniki, University Hospital of Targu Mures, Romania, University Hospital Heidelberg, Milpark Hospital, University of Minnesota, Royal Prince Alfred Hospital, Sydney, Australia, Fiona Stanley Hospital, Sunshine Coast University Hospital, China-Japan Friendship Hospital, Medical University of Graz, National Hospital Organization Okayama Medical Center, Royal Hobart Hospital, University Hospital, Zürich, Universidad Nacional de La Plata, Gold Coast Hospital and Health Service
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Jan 30, 2020
Primary completion
Jan 30, 2050 (estimated)
Completion
Jan 30, 2055 (estimated)
Last update
Apr 4, 2025

Study contacts

Raphael W Majeed
Contact
raphael.majeed@innere.med.uni-giessen.de
+49 641 985 42502

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion